Eli Lilly and Company (LLY): Deep Dive Research Report

Prepared April 2026 | The Investing Fieldguide

Section 1: What The Company Does

Eli Lilly makes drugs. Not devices, not diagnostics, not equipment - drugs. It discovers molecules that change how a disease progresses, manufactures those molecules at industrial scale, and sells them to patients through a global commercial network spanning roughly 125 countries. That sounds simple. The execution is not.

Founded on May 10, 1876 by Colonel Eli Lilly - a Union Army veteran and pharmaceutical chemist who was tired of ineffective remedies - the company began in a single room at 15 West Pearl Street in Indianapolis with just four employees, including Lilly's 14-year-old son Josiah. In its first year, it generated $4,470 in revenue. Its founding principle was straightforward and remains operative today: science should come first, and medicine should actually work.

The company's trajectory through history tracks the most important moments in modern medicine. In 1923, Lilly became the first company to mass-produce commercial insulin, commercializing the discovery made by Banting and Best at the University of Toronto and effectively giving diabetics a chance to survive. In 1955, Lilly manufactured 60% of Jonas Salk's polio vaccine for clinical trials. In 1988, it launched Prozac - the first SSRI antidepressant - which became the best-selling drug in the world and redefined psychiatric treatment. These were not lucky accidents. Each was the product of sustained R&D investment and a willingness to manufacture at scale what others could not.

The current company is structured around four therapeutic domains: Cardiometabolic Health (its engine), Oncology (its anchor), Immunology (its diversifier), and Neuroscience (its emerging bet). The first of these has undergone a transformation of historic proportions. What started as a diabetes franchise built on insulin and incretin therapies morphed, beginning in 2022, into something without precedent in pharmaceutical history - a drug class that is simultaneously the best-selling diabetes medicine, the most effective obesity treatment in clinical use, and a candidate for reducing cardiovascular mortality. That molecule is tirzepatide.

Tirzepatide works differently from the GLP-1 drugs that preceded it. Earlier drugs in this class - semaglutide being the reference - act on a single receptor in the gut and brain called the GLP-1 receptor, slowing gastric emptying, reducing appetite, and increasing insulin secretion. Tirzepatide does that too, but it also activates a second receptor: GIP (glucose-dependent insulinotropic polypeptide). The GIP receptor is found in adipose tissue, the brain, and the pancreas. Activating both receptors simultaneously creates a synergistic effect on insulin secretion, fat metabolism, and appetite suppression that appears to be meaningfully superior to GLP-1 activation alone. In clinical trials, tirzepatide achieved average weight loss of approximately 20% of body weight at the highest dose - outcomes that were previously achievable only through bariatric surgery. Semaglutide, the prior standard, achieved roughly 14%. That 6-percentage-point gap is not rounding error; it is the difference between a drug class and a breakthrough.

Tirzepatide is sold under two brand names: Mounjaro for type 2 diabetes and Zepbound for obesity. The molecule is identical. The regulatory approvals, indications, and commercial strategies are different. Together, these two products generated over $13 billion in a single quarter (Q4 2025). In 2025, the tirzepatide franchise was the best-selling pharmaceutical in the world, overtaking Keytruda from Merck.

The value proposition Lilly offers is not subtle. Patients who take tirzepatide lose meaningful amounts of weight, reduce their HbA1c dramatically, and - as shown in the SURPASS-CVOT trial - experience an 8% reduction in major adverse cardiovascular events and a 16% reduction in all-cause mortality compared to dulaglutide. These outcomes drive real demand from patients, physicians, payers, and governments. When a medicine delivers this kind of clinical differentiation, it does not need to compete primarily on price.

But Lilly is not a one-product company, even though tirzepatide commands the headlines. Verzenio (abemaciclib), its CDK4/6 inhibitor in breast cancer, generated over $5 billion in 2024 and holds the top position in its class. Kisunla (donanemab), its anti-amyloid antibody for Alzheimer's disease, captured over 50% of the amyloid-targeting market within months of broader launch and holds a genuinely differentiated clinical profile. The pipeline contains orforglipron - an oral GLP-1 pill awaiting FDA approval in Q2 2026 - and retatrutide, a triple agonist (GLP-1/GIP/glucagon) that produced 26% average weight loss in Phase 3 and could represent the next step-change beyond tirzepatide.

The business model is vertically integrated discovery-to-patient: Lilly discovers compounds internally, runs clinical trials, manufactures at proprietary facilities, and deploys a global commercial salesforce. It does not rely on a contract manufacturing organization for its core molecules. Manufacturing is, in fact, one of Lilly's most significant competitive advantages right now - and its most significant near-term constraint.

Section 2: Business Segments

Lilly operates as a single reporting segment under accounting rules - it does not break out revenue by therapeutic area in the financial statements. However, its commercial organization and internal structure is clearly divided into four therapeutic businesses: Cardiometabolic Health, Oncology, Immunology, and Neuroscience. Understanding these separately is essential to understanding where the growth comes from, where the risk sits, and what management is actually betting on.

Cardiometabolic Health

This is, by a very wide margin, the revenue engine of the company. Cardiometabolic encompasses all products related to diabetes, obesity, heart disease, and metabolic conditions. Tirzepatide - sold as Mounjaro and Zepbound - sits here. So do legacy products including Trulicity (dulaglutide), Jardiance (empagliflozin), Humalog (insulin lispro), and older insulin formulations.

In Q4 2024, Mounjaro generated $3.53 billion and Zepbound generated $1.91 billion - in a single quarter. By Q3 2025, the tirzepatide franchise had grown to $10.1 billion in a single quarter, making it the fastest-scaling drug in pharmaceutical history. Full-year 2025 tirzepatide revenues exceeded approximately $38-40 billion across the franchise.

The capability that defines this segment is Lilly's proprietary understanding of incretin biology - particularly the dual GIP/GLP-1 mechanism. Lilly's scientists understood, before the rest of the industry, that activating GIP alongside GLP-1 would produce additive metabolic benefits. That scientific insight, combined with years of optimization work on the molecular structure (specifically the C20 fatty diacid modification that enables once-weekly subcutaneous injection by extending the molecule's half-life to five days), produced a product that outperforms all competitors on every clinical endpoint that matters to patients and physicians.

The segment also contains the next two generations of the franchise. Orforglipron is an oral small-molecule GLP-1 agonist - taken daily in pill form - that does not require injection, refrigeration, or special handling. This is architecturally different from existing GLP-1 drugs (which are peptides requiring injection) and could dramatically expand the addressable market to patients who refuse injection. Orforglipron achieved 12.4% average body weight loss in its ATTAIN-1 Phase 3 trial and beat oral semaglutide (Novo Nordisk's Rybelsus) in a head-to-head trial on both A1C reduction and weight loss. The FDA is expected to approve orforglipron for obesity in Q2 2026. Retatrutide adds a third receptor to the mix - glucagon - creating a GLP-1/GIP/glucagon triple agonist. By activating glucagon receptors, retatrutide increases hepatic fat burning. In Phase 3 trials, it produced weight loss of up to 26% - and in some cohorts, up to 71 pounds of absolute weight reduction. The scale of that outcome is structurally bariatric. Multiple Phase 3 trials are expected to read out by end of 2026 before an FDA submission.

Why does this segment exist separately from oncology and immunology? Because the science, customer base, manufacturing chemistry, commercial infrastructure, and competitive dynamics are entirely different. Metabolic disease drugs are small molecules or peptide injectables, sold into primary care and endocrinology, requiring massive manufacturing capacity for high-volume dosing. That is a fundamentally different business from selling a targeted antibody into oncology.

Cardiometabolic accounts for roughly 65-70% of Lilly's total revenue and is growing faster than any other segment. However, it carries the most pricing risk - specifically from the Inflation Reduction Act's Medicare drug pricing negotiations and from PBM formulary management decisions.

Oncology

Lilly's oncology business is built around precision medicine - the idea that you can match a targeted therapy to the specific molecular profile of a patient's tumor and achieve outcomes that broad chemotherapy cannot. This segment currently has three meaningful products in market: Verzenio (abemaciclib), Jaypirca (pirtobrutinib), and a set of earlier-stage therapies.

Verzenio is a CDK4/6 inhibitor. Cyclin-dependent kinases 4 and 6 are proteins that drive cell division. In hormone receptor-positive, HER2-negative breast cancer - the most common breast cancer subtype - these kinases are often overactivated, causing uncontrolled tumor growth. Blocking CDK4 and CDK6 slows or stops this proliferation. What makes Verzenio different from Pfizer's Ibrance (palbociclib) and Novartis's Kisqali (ribociclib) is a combination of clinical differentiation and dosing flexibility. Verzenio is the only CDK4/6 inhibitor approved for early-stage breast cancer (adjuvant use after surgery) in patients at high risk of recurrence - an indication both Pfizer and Novartis pursued but Pfizer failed to win. Additionally, Verzenio has a more selective binding profile that reduces neutropenia (dangerous drop in white blood cells) compared to Ibrance, which matters enormously to oncologists making treatment decisions. In the CDK4/6 class, Verzenio generated $5.7 billion in 2025, making it the top product in its class, though Novartis's Kisqali grew faster (adding $1.75 billion in incremental revenue in 2025 vs. Verzenio's $416 million) and is catching up through a broad early-stage breast cancer trial win.

Jaypirca (pirtobrutinib) is a non-covalent BTK inhibitor for B-cell malignancies including chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), and Waldenström's macroglobulinemia. The BTK (Bruton's tyrosine kinase) inhibitor class was pioneered by AbbVie's Ibrutinib and AstraZeneca/BeiGene's Zanubrutinib, but these "covalent" BTK inhibitors bind irreversibly to the kinase and, over time, tumors can develop a mutation (C481S) that breaks the binding. Jaypirca binds non-covalently - reversibly - and therefore retains activity against these resistance mutations. It targets the population of patients who have already failed a covalent BTK inhibitor, which is a growing population as first-line covalent BTK usage increases. The BRUIN CLL-314 trial demonstrated non-inferiority against the current standard of care for response rate, confirming Jaypirca's clinical utility in this line of therapy. Lilly also acquired Point Biopharma in 2023, adding radioligand therapy capabilities to the oncology segment.

The pipeline includes olomorasib (KRAS G12C inhibitor), a mutation found in approximately 13% of non-small cell lung cancer and 3-4% of colorectal cancer. KRAS was considered "undruggable" for decades because its molecular surface offered no binding pocket for a drug. Amgen's sotorasib was the first approved KRAS G12C inhibitor in 2021, followed by Mirati/Bristol-Myers Squibb's adagrasib. Olomorasib is being developed in combination with other targeted agents to address the resistance that develops to first-generation KRAS inhibitors. A Phase 3 adjuvant lung cancer trial was initiated in Q1 2025.

Oncology accounts for roughly 15-20% of Lilly's revenue. It is the segment management describes as the longest-duration revenue bet - these cancers are chronic, the drugs are high-value, and the recurring patient population provides stable revenue. Verzenio's growth is plateauing in the U.S. (management explicitly said in the Q4 2025 call that the early breast cancer market has "reached a plateau"), but international expansion and new indications provide runway.

Immunology

Lilly's immunology segment covers inflammatory and autoimmune conditions: psoriasis, psoriatic arthritis, rheumatoid arthritis, atopic dermatitis, inflammatory bowel disease (both ulcerative colitis and Crohn's disease), and ankylosing spondylitis.

The core product is Taltz (ixekizumab), an IL-17A inhibitor for plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis. In 2024, Taltz generated $3.26 billion in revenue, growing 18%. The immunology segment also includes Olumiant (baricitinib), a JAK inhibitor developed with Incyte for rheumatoid arthritis (and deployed during COVID for hospitalized patients), and two newer, faster-growing products: Omvoh (mirikizumab) and Ebglyss (lebrikizumab).

Omvoh is an IL-23 inhibitor approved for both ulcerative colitis and Crohn's disease. The IBD market is dominated by anti-TNF therapies (Humira, Remicade) and newer biologics (Stelara from J&J, Rinvoq from AbbVie). Omvoh's differentiation comes from its specific mechanism - targeting IL-23 p19 - which produces durable remission in a meaningful subset of IBD patients, including those who have already failed anti-TNF therapy. Omvoh's Crohn's approval in Q4 2024 opened a second major indication.

Ebglyss is an IL-13 inhibitor for atopic dermatitis (eczema). The atopic dermatitis market is contested between Dupixent (dupilumab) from Sanofi/Regeneron - the undisputed market leader with over $14 billion in annual revenue - and several newer entrants including Ebglyss and Rinvoq (AbbVie). Dupixent blocks both IL-4 and IL-13; Ebglyss selectively blocks only IL-13, which some physicians favor for its cleaner mechanism. U.S. Ebglyss prescriptions grew 25% in Q3 2025 versus Q2 2025, indicating genuine commercial momentum, though it remains a small fraction of Dupixent's volume.

The immunology segment generates roughly 10-12% of total Lilly revenues. It is strategically important not because it is the largest segment today, but because autoimmune diseases are chronic, requiring long-term therapy, and the segment provides revenue diversification away from the tirzepatide concentration. Management's investment in three distinct immunology mechanisms (IL-17, IL-23, IL-13) reflects a deliberate bet on owning multiple slots in the IBD and dermatology treatment algorithm as the market continues to shift from broad anti-TNF therapy to more targeted approaches.

Neuroscience

Neuroscience is the smallest segment today and the one with the longest potential runway. The segment's primary current product is Kisunla (donanemab), an anti-amyloid antibody approved in July 2024 for early symptomatic Alzheimer's disease. The segment also includes mature products like Cymbalta (duloxetine, now largely generic), migraine treatments (Emgality, an anti-CGRP antibody), and Verzenio in some geographies.

Kisunla's mechanism is specific: it targets a modified, pyroglutamated form of amyloid-beta plaque that accumulates in the brains of Alzheimer's patients. Unlike Biogen/Eisai's Leqembi (lecanemab), which requires indefinite treatment, Kisunla has a defined treatment endpoint - when PET imaging shows that amyloid plaques have been cleared to minimal levels (defined as less than 11 centiloids), the drug is discontinued. This has two advantages: reduced total treatment burden and lower cumulative ARIA risk. By Q3 2025, Kisunla had captured over 50% of the amyloid-targeting therapy market, with prescriptions growing 50% sequentially in Q3 2025 and EU approval secured in September 2025.

The key challenge for Kisunla is ARIA - amyloid-related imaging abnormalities. ARIA-E (brain swelling) occurred in roughly 20-24% of trial patients, and ARIA-H (microhemorrhages) in 27-31%. Most are asymptomatic and resolve, but they require MRI monitoring and add clinical infrastructure cost and burden. Lilly's modified titration regimen, approved by the FDA in July 2025, reduced ARIA-E by 41% compared to the original dosing - a meaningful safety improvement that should accelerate commercial uptake.

The neuroscience segment represents a long-term option on the Alzheimer's market. With 55 million people globally living with dementia (the large majority being Alzheimer's) and no existing disease-modifying treatments other than the anti-amyloid antibodies, the potential is enormous - but so is the infrastructure requirement. Neurologists need PET imaging capability, infusion centers, and MRI monitoring. Scaling this requires healthcare system investment, not just drug availability.

Segment Summary

Section 3: Products and Business Detail

The Tirzepatide Franchise: Mounjaro and Zepbound

Tirzepatide is a 39-amino acid synthetic peptide. Its architecture begins with the native GIP sequence, onto which a 20-carbon fatty diacid chain (C20 fatty diacid) is attached via a linker. When injected subcutaneously, this fatty acid tail enables tirzepatide to bind to albumin in the bloodstream - the binding dramatically extends the molecule's residence time from hours (native GIP has a half-life of minutes) to approximately five days, which is what makes once-weekly dosing possible. The molecule simultaneously activates GIP receptors (with affinity matching native GIP) and GLP-1 receptors (with approximately five-fold lower affinity than native GLP-1, but biased toward cAMP signaling over beta-arrestin recruitment, meaning the receptor does not internalize as fast). The result is a uniquely balanced pharmacological signal: strong enough GLP-1 activation to drive appetite suppression and glucose control, combined with GIP activation that amplifies insulin secretion, promotes fat breakdown in adipose tissue, and appears to reduce the nausea side effects that limit higher GLP-1 dosing.

In clinical trials:

• SURPASS trials (diabetes): Average HbA1c reduction of 2.0-2.4% vs. approximately 1.5% for semaglutide; 5-9 mg weight loss
• SURMOUNT trials (obesity): Average weight loss of 15-22.5% of body weight at 72 weeks at the highest 15 mg dose
• SURMOUNT-OSA: Approved for obstructive sleep apnea - tirzepatide reduced the apnea-hypopnea index by 25-30 events/hour in non-CPAP users
• SURPASS-CVOT: 8% reduction in MACE-3 (cardiovascular death, non-fatal heart attack, non-fatal stroke) vs. dulaglutide, and 16% lower all-cause mortality - published 2025

Mounjaro (tirzepatide for diabetes, approved 2022) comes in doses of 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg weekly injection pens. Zepbound (tirzepatide for obesity, approved November 2023) uses the same dose range. Zepbound also introduced a vial format for direct-to-patient compounding pharmacies, which has been an important access vehicle: by Q2 2025, cash-pay vials represented 20% of total U.S. Zepbound prescriptions and 35% of new prescriptions - meaning a substantial portion of patients are paying out of pocket at discounted prices rather than waiting for insurance coverage.

Pipeline: Orforglipron

Orforglipron is structurally different from tirzepatide. It is a small-molecule GLP-1 receptor agonist - meaning it is not a peptide, it does not need injection, and it does not require refrigeration. It is taken as a daily oral tablet. This matters enormously for market expansion: a meaningful subset of the 100+ million Americans eligible for GLP-1 therapy has refused injectable medications, and international markets (particularly lower-income countries) face cold-chain distribution challenges that make injectable GLP-1s impractical.

In Phase 3 trials:

• ACHIEVE-1 (diabetes): A1C reduction of 1.3-1.6% from baseline; 65% of patients achieved A1C ≤6.5%
• ATTAIN-1 (obesity): Average weight loss of 12.4% (27+ pounds) at the highest dose; 40% of patients lost more than 15% of body weight
• ACHIEVE-3 (head-to-head vs. oral semaglutide): Orforglipron demonstrated superiority on both A1C reduction and body weight loss - a clean head-to-head win over the only competing oral GLP-1 drug on the market

The FDA is expected to approve orforglipron for obesity in Q2 2026, with the type 2 diabetes submission following. International regulatory submissions are underway for most major markets, with launches anticipated in 2027. The commercial implications are large: an oral pill removes the injection barrier, eliminates cold-chain requirements, and could reach patients in markets where injectable biologics are logistically impractical.

Pipeline: Retatrutide

Retatrutide is the most potent molecule in Lilly's metabolic pipeline. It is a triple agonist, activating GLP-1, GIP, and glucagon receptors simultaneously. Adding glucagon receptor activation is the incremental innovation over tirzepatide. Glucagon is a hormone that in normal physiology raises blood glucose - but its activation in adipose tissue and liver also drives thermogenesis (calorie burning) and fat oxidation (fat breakdown). In a well-designed obesity drug, you want the fat burning from glucagon without the blood glucose raising effect - tirzepatide's GLP-1 activation counterbalances the glucagon effect.

Phase 3 results for retatrutide showed:

• Average weight loss of up to 26% of body weight
• In some cohorts, average absolute weight loss exceeding 71 pounds
• Discontinuation rates were higher in patients with lower starting BMI due to "perceived excessive weight loss" - a genuinely novel safety signal that reflects the drug's potency

Six Phase 3 trials are expected to read out by end of 2026. Lilly has not yet filed for regulatory approval; this is 2027+ commercialization territory. Clarivate projects retatrutide could generate $30 billion annually by 2031.

Verzenio (Abemaciclib)

Verzenio is taken twice daily as an oral tablet, unlike competitors Ibrance (monthly oral dosing cycle, 3 weeks on / 1 week off) and Kisqali (daily oral dosing, 3 weeks on / 1 week off). The continuous dosing schedule is a clinical differentiator: abemaciclib has a distinct selectivity profile, with stronger CDK4 relative to CDK6 inhibition. This translates to lower rates of neutropenia - the class-defining toxicity of CDK4/6 inhibitors - enabling continuous administration without the mandatory rest weeks. Neutropenia rates with Verzenio in clinical trials were 46% (vs. 83% with Ibrance), grade 3+ rates 27% vs. 66%.

The key regulatory differentiation is the adjuvant indication. In the monarchE trial, Verzenio showed significant improvement in invasive disease-free survival in early-stage, high-risk HR+/HER2- breast cancer patients post-surgery. Ibrance failed its analogous trial (PALLAS). This gave Verzenio a unique indication in the early-stage setting - an addressable population orders of magnitude larger than the metastatic population where CDK4/6 inhibitors were originally approved.

Verzenio generated approximately $5.7 billion in 2025 revenue. Growth has slowed considerably - the U.S. early breast cancer market has, per management, "reached a plateau." International markets (EU, Japan, China) provide continuing growth. The competitive threat from Kisqali is real: Novartis added $1.75 billion in incremental Kisqali revenue in 2025 vs. Verzenio's $416 million - and Kisqali has now won a broad early-stage breast cancer trial (NATALEE) that may widen its approved indication. Verzenio is transitioning from rapid growth to steady cash generation.

Kisunla (Donanemab)

Kisunla is a monoclonal antibody (IgG1) that binds specifically to N3pG amyloid-beta - a pyroglutamated form of amyloid-beta found in established plaques. This is different from how Leqembi (lecanemab) works: Leqembi targets soluble amyloid-beta protofibrils before they deposit as plaques. Kisunla works on deposited plaques and is therefore indicated for patients with confirmed amyloid pathology on PET imaging or CSF biomarker testing, who are in the mild cognitive impairment or early dementia stage.

The key patient selection feature is tau stratification. Participants in the TRAILBLAZER-ALZ 2 Phase 3 trial were divided into low/medium tau and high tau groups. In the intermediate tau population (the primary analysis), Kisunla slowed cognitive decline on the iADRS scale by 40% at 76 weeks compared to placebo. Patients who started the trial with low tau burden - earlier in the disease continuum - showed the most dramatic slowing. This is the mechanism rationale for early diagnosis and treatment.

Kisunla's defined treatment endpoint is unique: patients can stop the drug when their PET scan shows amyloid clearance below 11 centiloids. Approximately 47% of patients in the trial achieved this endpoint by 24 weeks and 72% by 52 weeks. Once treatment is stopped, amyloid does not immediately re-accumulate - the benefit persists. This has real economics: a patient taking Kisunla for 12-18 months and then stopping is less expensive to treat than a patient on indefinite Leqembi infusions.

Kisunla requires MRI monitoring for ARIA. The modified titration regimen (starting at 700 mg, escalating to 1400 mg) approved in July 2025 reduced ARIA-E rates by 41% compared to the original fixed-dose regimen. This safety improvement is commercially significant because ARIA is the main reason neurologists hesitate before prescribing.

Immunology Products

Taltz (ixekizumab): An IL-17A inhibitor. IL-17A is a cytokine that drives the inflammatory cascade in psoriasis, psoriatic arthritis, and ankylosing spondylitis. Taltz is injected subcutaneously every 4 weeks after induction. Competitors include Cosentyx (secukinumab, Novartis) and Tremfya (guselkumab, J&J) in psoriasis. Taltz's differentiation is clinical depth of response - PASI 100 (complete skin clearance) rates are among the highest in class. Revenue $3.26 billion (2024), growing 18%.

Omvoh (mirikizumab): An IL-23 p19 subunit inhibitor approved for ulcerative colitis and Crohn's disease. IL-23 drives the Th17 inflammatory pathway central to IBD. Omvoh's induction is IV, maintenance is subcutaneous, administered every 8 weeks. It competes with Stelara (ustekinumab, J&J - IL-12/23 inhibitor), Skyrizi (risankizumab, AbbVie - IL-23 p19 inhibitor), and Tremfya in IBD.

Ebglyss (lebrikizumab): An IL-13 inhibitor for atopic dermatitis. Blocks the IL-13 cytokine directly, rather than its receptor. Competes primarily with Dupixent (dupilumab, Sanofi/Regeneron - the IL-4/13 dual blocker and category leader), Rinvoq (upadacitinib, AbbVie - JAK inhibitor), and Adbry (tralokinumab, LEO Pharma). Ebglyss's selective IL-13 blockade vs. Dupixent's dual IL-4/IL-13 blockade produces a slightly different side-effect profile; some physicians prefer the cleaner mechanism. Commercial uptake has been solid but it remains a niche player against Dupixent's dominance.

Manufacturing Operations

Lilly's manufacturing infrastructure is simultaneously its most important strategic asset and its most significant growth constraint. The company has committed to total U.S. manufacturing investment exceeding $50 billion since 2020 - a scale that is extraordinary for a single company.

Key facilities:

• Lebanon, Indiana (RTP API Plant): $9 billion investment (increased from initial $3.7B); active pharmaceutical ingredient manufacturing for tirzepatide and pipeline molecules; expected to begin production late 2026 with scale-up through 2028. This is the single most consequential capital project in Lilly's history.
• Indiana Medicine Foundry: $4.5 billion R&D and manufacturing hybrid facility, 30 miles northeast of Indianapolis at the LEAP Research and Innovation District; focused on connecting research-grade synthesis with manufacturing-scale production.
• Research Triangle Park, North Carolina: $450 million expansion; parenteral filling, device assembly, packaging for incretin injectables.
• Concord, North Carolina: $1 billion biologics campus (800,000 sq ft, six buildings); expected operational completion 2025.
• Virginia: New facility for bioconjugate antibodies (announced Q3 2025).
• Texas: New facility for small molecules including orforglipron (announced Q3 2025).
• Puerto Rico: Expansion for existing fill-finish operations.
• Limerick, Ireland: Nearly $1 billion investment in monoclonal antibody manufacturing; Lilly's most technically advanced biotech facility.
• Netherlands: $3 billion new manufacturing facility announced November 2025.

The production ramp from these facilities has been carefully tracked in management communications. Lilly produced 1.6x the number of sellable incretin doses in H1 2025 compared to H1 2024. The Lebanon, Indiana API plant - the cornerstone of long-term supply - is not expected to come fully online until 2028. Until then, Lilly is supply-constrained on tirzepatide. That constraint is both a near-term revenue cap and, paradoxically, a competitive moat: the capital and know-how required to manufacture GLP-1 peptides at this scale are not easily replicated.

Section 4: Customers

Who Buys Lilly's Products

Lilly's commercial reach operates through three distinct customer relationships depending on the product type: the prescribing physician (who decides which drug to use), the payer (who decides whether insurance covers it and at what cost-share), and the patient (who ultimately takes the drug and bears the out-of-pocket burden if coverage is limited).

For Tirzepatide (Mounjaro/Zepbound)

The prescribing decision sits with primary care physicians and endocrinologists for Mounjaro, and with a broader base of primary care physicians and obesity medicine specialists for Zepbound. Unlike specialty oncology drugs that require highly specialized prescribers, GLP-1 prescriptions are largely written in primary care - meaning Lilly's commercial salesforce is large and diverse. The sales cycle is short: a physician who has seen the clinical data and has a patient who qualifies can write the first prescription in one visit. What drives the physician's choice between Mounjaro/Zepbound and Novo Nordisk's Ozempic/Wegovy is a combination of clinical outcomes (tirzepatide wins on weight loss and A1C), formulary access (which drug the patient's insurance covers), and patient experience/tolerability (both classes have similar GI side effect profiles, with tirzepatide's dual mechanism associated with somewhat lower nausea rates at comparable efficacy doses).

The payer relationship is where Lilly faces its most significant commercial friction. Pharmacy benefit managers (PBMs) - companies like CVS Caremark, Express Scripts, and OptumRx - manage formulary placement for hundreds of millions of covered lives. In July 2025, CVS Caremark excluded Zepbound from its commercial formularies in favor of competing products, creating a meaningful Q3 headwind that management explicitly acknowledged in the Q2 2025 earnings call. This exclusion illustrates the leverage PBMs hold: they can effectively redirect large patient volumes by removing a preferred product from coverage.

The direct-to-patient channel - Lilly's LillyDirect program offering vials at discounted prices (approximately $349/month) - was explicitly designed to provide an insurance-independent access pathway. This is both a commercial strategy and a political response to pricing criticism: if patients can access tirzepatide without insurance at a price competitive with out-of-pocket costs in other countries, the argument that pricing is a barrier weakens.

Internationally, the dynamic is different. Mounjaro has launched in 55 countries, but outside the U.S., reimbursement for obesity indications is rare. Approximately 75% of non-U.S. Mounjaro/Zepbound revenue comes from patients paying entirely out of pocket. This creates a self-selected, price-insensitive customer base internationally while limiting total addressable market to wealthier patients.

For Verzenio (Breast Cancer)

The buying decision is made by oncologists, specifically breast oncology specialists. The sales cycle involves a treating oncologist reviewing the monarchE trial data, discussing options with the patient, and selecting a CDK4/6 inhibitor based on clinical profile and formulary access. Switching costs are moderate: once a patient starts a CDK4/6 inhibitor in the adjuvant setting (after surgery, before recurrence), they are typically committed to 2-5 years of therapy. Changing regimens requires patient and physician agreement and carries some risk of interrupting proven benefit. The switching cost in metastatic disease is lower because the treatment calculus changes at each disease progression event.

Hospital/specialty pharmacy is the primary dispensing channel. In the U.S., Verzenio is covered under Medicare Part D and most commercial formularies. Patient co-pay assistance programs maintain access for commercially insured patients.

For Kisunla (Alzheimer's)

The patient journey for Kisunla is the most infrastructure-intensive of any Lilly product. A patient must first see a neurologist or dementia specialist, who orders either a PET amyloid scan (expensive, often $3,000-5,000 and frequently not covered by insurance) or a cerebrospinal fluid biomarker test to confirm amyloid pathology. If positive, the patient is then started on monthly IV infusions, which require an infusion center and ongoing MRI monitoring for ARIA. The prescribing physician is a neurologist; the care coordinator manages infusion scheduling and safety monitoring.

This high-infrastructure requirement creates a natural market gating mechanism - only patients with access to neurology practices equipped with PET imaging and infusion capabilities can be treated. Medicare now covers the drug and diagnostic testing (after an initially restrictive coverage determination was replaced), but the physician network infrastructure is building slowly. Lilly has been investing in a Qualified Treatment Center program to help expand the number of sites equipped to prescribe and monitor Kisunla.

Switching costs across all products

Switching costs in branded pharmaceuticals have two components: clinical risk and administrative friction. For tirzepatide in obesity, the clinical cost of switching is real - patients who achieve significant weight loss face regain if they stop the drug, and switching to a less efficacious competitor means accepting lower outcomes. The administrative friction of switching payers' preferred product involves prior authorization resubmission and potential patient disruption.

For Verzenio in adjuvant breast cancer, switching involves interrupting a two-to-five year treatment protocol that has demonstrated survival benefit in high-risk patients. The physician would need a clinical reason (toxicity, disease progression) to change course.

For Kisunla, once ARIA monitoring protocols are in place and the patient has begun amyloid clearance, switching to a competitor mid-treatment is unusual given the defined treatment endpoint that Kisunla offers.

Revenue Concentration

Tirzepatide represents approximately 60%+ of Lilly's total revenue. This is concentration risk at the product level, even though the product itself serves multiple indications and is structurally growing. No single customer represents a material portion of revenue - the U.S. government (through Medicare/Medicaid) is the largest payer block but is not a single counterparty in the same way a named corporate customer would be.

Section 5: Competitive Landscape

GLP-1 and Cardiometabolic

The primary competitor is Novo Nordisk. This is not a large field of competitors - GLP-1 drugs require years of clinical development, billions in R&D, unique manufacturing capabilities for peptide synthesis, and global commercial infrastructure. The barriers to entry are extraordinary.

Novo Nordisk is the reference competitor. Semaglutide (Ozempic for diabetes, Wegovy for obesity, Rybelsus for oral diabetes) has been the market leader in the GLP-1 class until 2025. Ozempic generated peak revenues over $23 billion in 2023 before Lilly's tirzepatide overtook it. Novo's challenge is threefold:

1. Tirzepatide is clinically superior - approximately 20% average weight loss vs. ~14% for weekly semaglutide
2. Novo's oral semaglutide (Rybelsus) was beaten head-to-head by Lilly's orforglipron in Lilly's ACHIEVE-3 trial
3. Novo's earnings trajectory reversed: Q4 2025 revenue declined 7.6% YoY; the company cut 9,000 jobs and warned of pricing headwinds from Most Favoured Nation pricing agreements

Novo does retain competitive advantages: first-mover advantage internationally (Ozempic is well-established in markets where Mounjaro is still launching), an oral obesity drug (oral Wegovy approved December 2025) to compete with orforglipron, and long-standing relationships with diabetologists globally. But the clinical data consistently favors tirzepatide.

Amgen has the most technically interesting competitor: MariTide (AMG133), a GLP-1 agonist combined with a GIPR antagonist (it blocks GIP signaling rather than activating it). The theoretical benefit is weight loss without weight regain during drug holidays - Phase 2 data showed weight loss maintained at 52 weeks after dosing stopped, which no GLP-1/tirzepatide does. Phase 3 trials are underway; commercial launch is 2027+ at the earliest. The scientific question of GIP agonism (Lilly's approach) vs. GIP antagonism (Amgen's approach) is a genuine debate in metabolic medicine.

Viking Therapeutics (VK2735) and Structure Therapeutics are smaller biotechs with oral and injectable GLP-1 programs in earlier stages. They represent potential future competition or acquisition targets, not current commercial threats.

AstraZeneca has tirzepatide-like clinical ambitions with cotadutide (GLP-1/glucagon dual agonist) and other metabolic programs but is significantly behind Lilly in both Phase 3 data and commercial scale.

The structural competitive moat in GLP-1 is manufacturing capability. Tirzepatide requires peptide synthesis at industrial scale - a process requiring specialized manufacturing equipment, chemistry expertise, and multi-year capacity buildup. Lilly's $9 billion Lebanon, Indiana API plant is a capital barrier to entry that no potential new competitor can replicate in less than 5-7 years. Supply creates market share; Lilly's incretin dose production grew 1.6x year-over-year and is scaling further. The company that can make enough drug will win.

Oncology

CDK4/6 Inhibitors: The competitive triangle is Verzenio (Lilly), Kisqali (Novartis), and Ibrance (Pfizer). Pfizer's Ibrance is structurally declining - it failed the key adjuvant trial, has the worst tolerability profile, and is losing market share. Ibrance's revenue was $4.1 billion in 2025 on its fourth consecutive annual decline. Kisqali is growing rapidly, adding $1.75 billion in 2025 incremental revenue driven by the NATALEE trial data showing broad early-stage breast cancer benefit. Verzenio's growth is slowing in the U.S., though international markets and sub-indication expansions provide modest runway. The risk for Verzenio is that Kisqali's NATALEE data creates a competing adjuvant narrative. Verzenio currently retains the most comprehensive CDK4/6 efficacy dataset - specifically the 5-year monarchE follow-up showing sustained invasive disease-free survival - but this is not an uncontested position.

BTK Inhibitors: Jaypirca competes against AbbVie's Imbruvica (ibrutinib) and AstraZeneca/BeiGene's Calquence (acalabrutinib) and BeiGene's Brukinsa (zanubrutinib). In the specific indication of post-covalent BTK inhibitor failure, Jaypirca has no approved competitor. The risk is that physicians use more efficacious upfront regimens (venetoclax combinations) that delay or prevent reaching the line where Jaypirca is indicated.

Immunology

Psoriasis (Taltz): The main competitors are Cosentyx (Novartis), Skyrizi and Rinvoq (AbbVie), Tremfya (J&J), and Dupixent (Sanofi/Regeneron, in atopic dermatitis). Taltz competes on deep PASI 100 response rates. The immunology market is not winner-take-all - multiple drugs coexist, and formulary positioning drives volume more than clinical differentiation does.

Atopic Dermatitis (Ebglyss): Dupixent is the dominant product with $14+ billion in revenue and years of market experience. Ebglyss is gaining ground but competing against Dupixent head-to-head in a market Dupixent built is structurally difficult.

IBD (Omvoh): Stelara (J&J), Skyrizi (AbbVie), and Entyvio (Takeda) are the primary competitors. Omvoh's differentiation is the once-every-8-weeks maintenance dosing and the sequential IL-23 mechanism.

Alzheimer's Disease (Kisunla vs. Leqembi)

The only meaningful competition in anti-amyloid therapy is Leqembi (lecanemab) from Eisai and Biogen. Kisunla's advantages: defined treatment endpoint (stop when plaques are cleared), PET-confirmed plaque clearance allowing discontinuation, and slightly better 76-week cognitive outcomes in the trial population with intermediate tau. Leqembi's advantages: earlier mover in the U.S. market, biweekly dosing vs. monthly (easier infusion scheduling at some centers), and a broader clinical trial dataset. Market share data from Q4 2025 shows Kisunla at over 50% of the amyloid-targeting market, suggesting the defined endpoint narrative is resonating with both physicians and patients.

Barriers to Entry

In GLP-1s: capital requirements for peptide manufacturing ($5B+ for one API plant), clinical development timeline (7-10 years from discovery to approval), patent protection extending to mid-2030s for tirzepatide, regulatory expertise for large-molecule manufacturing, and an established physician relationship network.

In oncology: cancer drug development requires large Phase 3 trials across multiple years, regulatory expertise in oncology, and specialty pharmacy distribution relationships.

In immunology: the field is crowded but biosimilar risk is real for older products (Taltz, Olumiant). New entrants face the challenge of differentiating against established IL-17, IL-23, and JAK options.

In neuroscience: the Alzheimer's market requires an extraordinary infrastructure investment in diagnostics (PET imaging, CSF biomarkers), physician training, infusion centers, and safety monitoring. This deters generalist pharma companies.

Section 6: Industry

Demand Drivers for GLP-1/Metabolic Drugs

The foundational demand driver is obesity prevalence. Approximately 42% of American adults are obese (BMI >30) and 73% are overweight or obese. Globally, over 1 billion people are obese. Prior to GLP-1 drugs, effective pharmacological treatment was limited: older anti-obesity drugs had unacceptable safety profiles or modest efficacy, and bariatric surgery was effective but accessible to only a small fraction of patients. The arrival of tirzepatide and semaglutide created, for the first time, a pharmacological option that approaches surgical weight loss outcomes with an acceptable safety profile.

Demand is also driven by the downstream diseases that obesity causes or worsens: type 2 diabetes (approximately 38 million Americans), cardiovascular disease (the leading cause of death globally), obstructive sleep apnea, non-alcoholic fatty liver disease (NASH), and chronic kidney disease. Each of these secondary indications represents an incremental addressable population beyond obesity itself - and Lilly is actively pursuing FDA approvals for each.

Industry Size

The global GLP-1 receptor agonist market was approximately $66 billion in 2025 and is projected to reach $185 billion by 2033, implying roughly a 12-14% compound annual growth rate. For context, Lilly alone is guiding to $80-83 billion in total revenue in 2026, with the large majority coming from tirzepatide. By 2030, Wall Street broadly expects the global weight loss drug market to exceed $150 billion. Truist projects Lilly's obesity franchise alone could reach $101 billion in peak global revenue.

The U.S. currently accounts for roughly 70% of global GLP-1 demand. Internationally, reimbursement for obesity (as opposed to diabetes) is limited in most markets - most obesity prescriptions outside the U.S. are cash-pay. As government reimbursement expands internationally - driven by the health economic case that treating obesity prevents more expensive downstream hospitalizations - international demand should accelerate.

Regulatory Environment

The FDA approval process for a new obesity or diabetes drug requires a Phase 3 trial demonstrating safety and efficacy over at least one year, typically with 2,500-10,000 patients. Beyond approval, the FDA has increasingly required cardiovascular outcomes trial (CVOT) data to confirm drugs don't harm heart health. Tirzepatide's SURPASS-CVOT data showing cardiovascular benefit rather than harm was a pivotal regulatory and commercial milestone.

The Inflation Reduction Act of 2022 created the first mechanism for Medicare to negotiate drug prices directly. The law's Medicare Drug Price Negotiation Program selected 10 drugs for its initial negotiation round; tirzepatide and other GLP-1 drugs are likely candidates for future rounds. The 2026 guidance acknowledges a "low to mid-teens percentage" pricing headwind from government access agreements. Additionally, Medicaid - which covers approximately 80 million lower-income Americans - was previously expanding obesity drug coverage but several states (including California) reversed this decision in 2025-2026, citing budget constraints.

The compounding pharmacies that have been manufacturing copies of tirzepatide during the FDA drug shortage period are being phased out. The FDA removed tirzepatide from its drug shortage list, which requires compounders to cease production. This dynamic initially suppressed Zepbound prescription fills (patients shifted to compounded versions during shortage), and its reversal is expected to boost branded Zepbound demand.

Cyclicality

Pharmaceutical demand for chronic disease treatment is among the least cyclical of any industry. Diabetes, obesity, and cancer patients do not postpone treatment because of economic downturns - in many cases, these are life-or-death medications. The main risk in a recession is patients losing insurance coverage or being unable to afford co-pays, which is addressed by Lilly's direct-to-patient vial program. The business is fundamentally acyclical at the demand level; the risk is on the reimbursement and pricing side, not on underlying patient demand.

Oncology Industry Dynamics

Cancer incidence is growing globally, driven partly by aging populations. Breast cancer is the most common cancer in women globally, with approximately 2.3 million new diagnoses annually. CDK4/6 inhibitors are now standard of care in HR+/HER2- breast cancer, with penetration still growing in early-stage settings. The risk in this market is patent cliff exposure: abemaciclib has U.S. patent protection through the early 2030s.

Alzheimer's Industry Dynamics

The Alzheimer's drug development landscape has had over 200 failed clinical trials over 30 years. The approval of Leqembi and Kisunla represents the first validated, disease-modifying approach - anti-amyloid therapy - after decades of failure. The market is early: only a fraction of the 6.7 million Americans living with Alzheimer's have been diagnosed in the early stage appropriate for treatment. Infrastructure (PET imaging, infusion centers, neurologist capacity) is the binding constraint on growth, not drug availability. As diagnostic tools improve (blood-based biomarker tests for amyloid are advancing rapidly and could replace expensive PET imaging), the addressable patient pool will expand dramatically.

Section 7: Growth Triggers

All triggers sourced from the four most recent earnings calls: Q1 2025 (May 1, 2025), Q2 2025 (August 7, 2025), Q3 2025 (October 30, 2025), Q4 2025 (February 4, 2026).

• Orforglipron FDA approval and launch (obesity indication) expected in Q2 2026, with commercial launch to follow immediately. This is a new daily oral pill with no injection barrier, targeting the subset of the obesity market that has declined injectable therapy. (Q4 2025 concall, Feb 4 2026; Q3 2025 concall, Oct 30 2025; Q2 2025 concall, Aug 7 2025 - mentioned across all three most recent calls)

Management Q4 2025: "Orforglipron submission is expected to receive FDA approval in Q2 2026 for obesity treatment."

• Orforglipron diabetes submission expected following obesity approval; extends the label into the larger type 2 diabetes commercial market. (Q1 2025 concall, May 1 2025; Q3 2025 concall, Oct 30 2025)

• Lebanon, Indiana API plant expected to begin production late 2026, with full-scale operations through 2028, significantly expanding tirzepatide supply capacity. At $9 billion of capital investment, this is the most consequential manufacturing trigger in Lilly's history. (Q1 2025, Q2 2025, Q3 2025 concalls - repeated)

• Mounjaro international market launches: As of Q3 2025, Mounjaro had launched in 55 countries. Management highlighted continued rollout into additional markets, with each new country adding incremental out-of-pocket demand from an internationally price-insensitive patient base. 75% of non-U.S. incretin revenue is cash-pay. (Q3 2025 concall, Oct 30 2025)

• Retatrutide Phase 3 readouts: Six Phase 3 trials expected to read out by end of 2026, covering obesity, diabetes, and comorbidity populations. Positive data would enable regulatory submission, with commercialization potential starting 2027-2028. (Q3 2025 concall, Oct 30 2025)

• Medicare obesity coverage launch (July 1, 2026): The U.S. government agreed to expand access to obesity medicines to millions of Americans under Medicare, with coverage beginning July 1, 2026. This expands the commercially covered population for Zepbound meaningfully. (Q4 2025 concall, Feb 4 2026)

• Kisunla EU launch: European Commission marketing authorization received September 2025. Launch into the EU market is underway, representing a new geographic opportunity. (Q3 2025 concall, Oct 30 2025)

"Kisunla prescriptions grew 50% sequentially" and EU approval secured - management Q3 2025.

• Movalaplin Phase 3 initiated: A novel mechanism targeting elevated lipoprotein(a) - Lp(a) - with atherosclerotic cardiovascular disease. Lp(a) is a genetically inherited cardiovascular risk factor with no approved treatment; movalaplin is designed as a once-daily pill. Phase 3 trial initiation confirmed. (Q3 2025 concall, Oct 30 2025)

• Olomorasib Phase 3 adjuvant lung cancer: Phase 3 trial for the KRAS G12C inhibitor olomorasib in resected, adjuvant non-small cell lung cancer initiated. This is a large patient population with unmet need and no current targeted adjuvant therapy. (Q1 2025 concall, May 1 2025)

• Imlunestrant (Inlureo) approval and launch: Approved for ER-positive, HER2-negative, ESR1-mutated advanced breast cancer - a specific molecularly defined population that progresses on standard endocrine therapy. Newly approved oncology product adding to the commercial base. (Q3 2025 concall, Oct 30 2025)

• New Texas (orforglipron small molecule) and Virginia (bioconjugate antibody) facilities announced in Q3 2025, expanding the domestic manufacturing footprint beyond peptide injectables. (Q3 2025 concall, Oct 30 2025)

• Attain-Maintain study for orforglipron: A head-to-head trial assessing weight maintenance after switching patients from injectable GLP-1 competitors to orforglipron. Designed to demonstrate that the oral pill can maintain weight loss achieved on injectables, which would be a commercial permission structure for a large switching market. (Q3 2025 concall, Oct 30 2025)

Section 8: Key Risks

1. Pricing Pressure from Government Negotiation and PBM Formulary Management

Mechanism: The Inflation Reduction Act empowers Medicare to directly negotiate drug prices for the highest-spend medications. Tirzepatide will be subject to this negotiation once eligible (typically the medication must be marketed for a defined period before becoming eligible). When negotiated prices take effect, Lilly's U.S. average net price declines. Separately, PBMs can exclude Lilly products from preferred formulary positions, redirecting patients to competitor drugs (as CVS Caremark did with Zepbound in July 2025). Both mechanisms reduce per-unit revenue without reducing volume.

Management has already acknowledged a "low to mid-teens percentage" pricing headwind to 2026 growth. Q4 2025: "U.S. average realized prices declined 7% in Q4 2024 compared to prior year." This is not hypothetical - it is happening now. The risk is that pricing declines faster than volume grows, causing revenue growth to disappoint even against strong patient demand. High-probability, moderate-ongoing drag.

2. Tirzepatide Concentration Risk

A single molecule, tirzepatide, accounts for approximately 60%+ of Lilly's total revenue. If tirzepatide were to face a serious safety signal, a major PBM exclusion across all formularies, a breakthrough competitor that closes the efficacy gap, or a regulatory restriction (e.g., requiring more restrictive prescribing criteria), the impact on Lilly would be existential. The molecule has been used by tens of millions of patients with a robust safety profile, but the long-duration use data is still accumulating. No drug this new, used at this scale, has more than 5-6 years of real-world data. A rare but serious long-term side effect that emerges with scale - analogous to Vioxx's cardiovascular signal discovered post-approval - would be catastrophic. Low probability, catastrophic magnitude.

3. Manufacturing Execution Risk

Lilly is in the middle of the largest manufacturing buildout in its history. The Lebanon, Indiana plant - $9 billion and central to the long-term tirzepatide supply thesis - is not expected to reach full production until 2028. Building large-scale pharmaceutical manufacturing is technically complex; delays, equipment failures, regulatory hold-ups from the FDA's manufacturing quality inspection process (Form 483 observations, Warning Letters), or contamination events can set timelines back by 12-24 months. A manufacturing delay would mean Lilly cannot produce enough tirzepatide to meet demand, creating revenue shortfall and potentially opening a window for competitors. Moderate probability, significant financial impact.

4. Competitive Disruption from Next-Generation Molecules

Amgen's MariTide (AMG133) - a GLP-1 agonist / GIPR antagonist - showed in Phase 2 data that weight loss is maintained for an extended period after stopping the drug. If this holds in Phase 3, it represents a fundamental pharmacological differentiation: patients could take the drug for a defined treatment period, stop, and maintain weight loss without ongoing injection. For patients who see tirzepatide as requiring "lifetime" injections, a defined-course therapy could be highly attractive. Lilly's orforglipron and retatrutide programs are defensive weapons here, but MariTide's Phase 3 data (expected 2026-2027) represents genuine discontinuity risk if positive. Moderate probability, high commercial impact if confirmed.

5. PBM and Medicaid Coverage Erosion for Obesity

Lilly and Novo Nordisk both lobbied hard for Medicaid obesity drug coverage expansion. Several states (California being the most prominent) reversed planned Medicaid GLP-1 coverage due to budget constraints in 2025-2026. If this becomes a broader state-level trend, the Medicaid patient population - which is among the highest-obesity-prevalence demographic in the U.S. - remains largely uncovered, capping the addressable market for Zepbound. This is not catastrophic but meaningfully delays market penetration among the socioeconomically disadvantaged patients who arguably need these drugs most. Moderate probability, moderate volume drag.

6. Alzheimer's Diagnostic Infrastructure Bottleneck

Kisunla's clinical value is real, but commercial uptake is constrained by PET imaging access and neurologist capacity. If reimbursement for the diagnostic workup remains complex, if neurologists remain cautious about ARIA management, or if competing anti-amyloid therapies (including a blood-based biomarker diagnostic pathway that may favor Leqembi's existing clinical protocols) gain advantage, Kisunla's market penetration will remain slower than the underlying patient prevalence would suggest. Low to moderate probability, moderate revenue impact.

7. Verzenio Patent Cliff and Kisqali Competition

Verzenio's U.S. patents expire in the early 2030s. Management explicitly said in Q4 2025 that the U.S. early breast cancer market has "reached a plateau." Novartis's Kisqali is growing rapidly and may surpass Verzenio in total revenue within 1-2 years if Novartis executes its NATALEE trial-based label expansion effectively. Verzenio is not collapsing - it is transitioning from growth to mature cash generation - but this transition limits upside from the oncology segment. High probability of plateau, low risk of catastrophic decline.

8. Tariff and Geopolitical Risk

Lilly manufactures globally (U.S., Ireland, Singapore, Puerto Rico, others) and imports active pharmaceutical ingredients and finished goods. Expanded pharmaceutical tariffs - threatened in the broader trade policy environment as of early 2026 - could increase COGS for imported components. Management in Q1 2025 stated that "the announced tariffs do not materially change Lilly's 2025 financial outlook," but noted expanded tariffs could negatively impact results. The risk is policy uncertainty more than current financial impact. Moderate probability of escalation, manageable financial impact given the U.S. manufacturing expansion underway.

Section 9: Walk the Talk

Building the Credibility Record: Q1 2025 through Q4 2025

The four-concall record from Q1 2025 through Q4 2025 allows a direct test of whether Lilly management makes promises it can keep. The verdict is nuanced: management is consistently conservative on near-term guidance (setting numbers it exceeds) but sometimes optimistic about commercial timelines (particularly around formulary coverage dynamics).

Q1 2025: Setting Up the Year

In the May 1, 2025 call, management reaffirmed full-year 2025 guidance of approximately $58-61 billion in revenue despite an EPS miss (driven by acquired IPR&D charges, a one-time item). CEO David Ricks said: "We're mostly focused on executing our winning strategy, discovering, developing, and making new medicines." On tariffs, the team was explicit: announced tariffs "do not materially change Lilly's 2025 financial outlook." They guided to 1.6x incretin doses in H1 2025 vs. H1 2024. On orforglipron, they flagged seven Phase 3 readouts expected over the next 12 months and committed to an obesity regulatory submission by end-2025.

Q2 2025: Delivering on H1 Commitments

By August 7, 2025, H1 performance validated the guidance. Incretin doses produced were indeed 1.6x the prior year (as guided). Mounjaro had achieved market leadership in type 2 diabetes incretin prescriptions with over 50% share of new prescriptions - consistent with Q1 trajectory. Gross margin expanded to 85%, exceeding prior guidance for the direction of margin improvement. The ATTAIN-1 orforglipron trial data delivered: 12.4% weight loss at the highest dose, 40% of patients exceeding 15% - ahead of what many analysts expected. Management raised guidance to $60-62 billion - the second consecutive guidance raise, demonstrating the pattern of conservative initial guidance.

A candid risk disclosure also stands out: management explicitly acknowledged that the CVS Caremark formulary exclusion of Zepbound effective July 1, 2025 would "create a headwind to volume growth in Q3." This was transparent guidance in real time, not a post-hoc explanation. The willingness to flag a known headwind proactively rather than obscure it is credibility-positive.

Q3 2025: Execution Through the CVS Headwind

The Q3 earnings call delivered on the math: revenue grew 54% YoY, the guidance raise was to $63-63.5 billion (above the $60-62 billion raised in Q2), and the CVS headwind was absorbed without materially disrupting growth. Management had guided for a Q3 impact from CVS - and they delivered above the raised range anyway, demonstrating that the commercial organization found enough volume offset (international market growth, other formularies, direct cash-pay) to cushion the U.S. formulary headwind.

Zepbound's prescription market share reached 71% of new branded obesity prescriptions by end-Q3 - the Q1 concall had described Zepbound at roughly 60% TRx. The sequential share gain happened despite the CVS exclusion, which reflects the strength of underlying physician preference and patient demand.

Orforglipron hit another data point: the ACHIEVE-3 head-to-head vs. oral semaglutide showed superiority. Management had guided that orforglipron's data package "compared favorably" to Rybelsus - the actual head-to-head superiority claim was a meaningful upside to that language.

The commitment to produce "at least 1.8x incretin doses in H2 2025 vs. H2 2024" (guided in Q2) was tracking to delivery based on Q3 commentary.

Q4 2025: Full-Year Delivery and 2026 Framework

The full-year 2025 revenue of $65.2 billion fell at the top end of the raised guidance range ($63-63.5 billion given at Q3, then raised further). EPS of $24.21 against guidance of $23-23.70 given at Q3 was a beat. The company ended the year ahead of every guidance set at the start of the year.

Management guided 2026 revenue at $80-83 billion with EPS of $33.50-35. This implies ~25% revenue growth and ~40% EPS growth. The guidance acknowledges a "low to mid-teens percentage" pricing headwind explicitly - a candid accounting of the IRA and government negotiation impact that is more transparent than most pharma companies offer.

Two admissions in the Q4 2025 call are worth noting. First, on Verzenio: "The U.S. early breast cancer market has reached a plateau." This is a direct acknowledgment that a product contributing $5+ billion annually has reached peak growth in its most important market. It was not buried or euphemized - management said it plainly. That kind of transparency about a maturing asset is credibility-building. Second, on retatrutide: management noted that in lower-BMI patients, higher discontinuation rates due to "perceived excessive weight loss" are a genuine safety signal being monitored. This was an unprompted disclosure of a risk that could have been omitted from investor communications.

Overall Assessment

Lilly's management has demonstrated a consistent pattern of: (1) setting guidance at the start of a period that proves conservative, (2) raising guidance at each subsequent quarter as performance outpaces initial estimates, and (3) delivering at the top of or above raised guidance. This is not accidental - it reflects deliberate guidance conservatism combined with genuinely strong commercial execution. On risk disclosures, the team has been notably transparent: CVS formulary exclusion flagged proactively, Verzenio plateau named explicitly, retatrutide safety signal disclosed. There are no major promises clearly dropped or denied across the four-call record. The pattern is: this management does what they say, usually ahead of schedule.

Section 10: Scenarios

Bull Case

In the bull case, three things work simultaneously: the oral pill revolution, international reimbursement expansion, and the pipeline cascade.

Orforglipron is approved by the FDA in Q2 2026 as guided and launches commercially in the U.S. by mid-2026. The pill format removes the injection barrier for the segment of the market that has refused Mounjaro and Zepbound - estimated at tens of millions of potential patients. Physicians find it easier to prescribe to mildly-to-moderately obese patients who don't yet feel ready for a weekly injection. International launches of orforglipron in 2027 address markets where cold-chain injectable supply has been the limiting factor. The 75% cash-pay dynamic in international markets shifts as reimbursement begins in EU and Asian markets following orforglipron's simpler supply chain and lower manufacturing cost structure.

The Lebanon, Indiana manufacturing plant comes online on schedule in late 2026 and scales cleanly through 2027, ending the supply constraint on tirzepatide and allowing Lilly to service all demand without rationing. Mounjaro and Zepbound prescription volumes grow into the expanded supply, and pricing stabilizes as volume offsets the IRA headwind.

Retatrutide Phase 3 data reads out in 2026 showing 25%+ weight loss across all primary endpoints, confirming the triple agonist thesis. The FDA pathway becomes clear for a 2028 submission. Analysts begin modeling a sequential generation of tirzepatide -> orforglipron -> retatrutide as a 15-20 year franchise with deepening clinical differentiation at each step.

Kisunla adoption accelerates as blood-based biomarker tests for amyloid make diagnosis faster and cheaper, dramatically expanding the diagnosable early-Alzheimer's population. With simplified diagnostics and an improving ARIA safety profile from the modified titration regimen, Kisunla captures the majority of the addressable patient pool. Lilly's neuroscience segment reaches multi-billion scale by 2028.

In this scenario, Lilly's revenue trajectory toward $100 billion is visible within the current decade, and the pipeline provides clear succession to tirzepatide as it matures.

Base Case

The most likely path is strong but not flawless execution against the 2026 guidance.

Orforglipron is approved in Q2 2026 and launches, adding incremental volume but taking two to three years to reach meaningful commercial scale as physicians build experience with the oral formulation and formulary coverage is negotiated. The oral pill augments rather than replaces the injectable franchise; total incretin revenue continues growing but the growth rate moderates as the core tirzepatide franchise matures in the U.S.

Manufacturing capacity expands roughly on schedule, ending the most acute supply constraints by 2027, but the transition involves some production variability as the Lebanon plant scales. International Mounjaro growth continues driven by out-of-pocket demand in markets without reimbursement, though the growth rate is lower than U.S. growth because of limited payer coverage.

Verzenio holds steady internationally while U.S. growth plateaus as guided. Kisunla grows steadily but remains constrained by diagnostic infrastructure until blood-based biomarkers gain broader clinical adoption. The immunology segment (Omvoh, Ebglyss) contributes growing but modest revenue.

The 2026 revenue guidance of $80-83 billion is delivered around the midpoint, with EPS growth strong due to ongoing margin expansion from the favorable product mix toward tirzepatide (high-gross-margin) and operating leverage. Pricing pressure from IRA negotiations reduces price/unit but volume growth more than offsets it.

In this base case, Lilly executes through its known challenges - pricing headwinds, PBM friction, manufacturing ramp - and emerges in 2027-2028 with an even larger manufacturing base, an approved oral GLP-1, and retatrutide nearing submission.

Bear Case

The bear case does not require any single catastrophic event - it requires several medium-probability challenges converging simultaneously.

The CVS-type formulary exclusion becomes industry-wide: as Novo Nordisk's oral semaglutide (approved December 2025) competes head-to-head with orforglipron and Novo's salesforce aggressively contests formulary access, PBMs find themselves with pricing leverage to pit the two pills against each other. Lilly faces the choice of discounting significantly to maintain preferred access or accepting formulary exclusions across major accounts. Net price realization falls faster than volume growth, and revenue growth disappoints against the $80-83 billion guidance.

Meanwhile, the Lebanon, Indiana manufacturing plant encounters FDA inspection issues - a Form 483 observation related to manufacturing process controls, a common occurrence for complex biologics facilities starting up - delaying commercial production by 12-18 months. Supply of tirzepatide injectable remains constrained, capping volume growth at a time when competitive alternatives have more supply. The supply gap emboldens PBMs who know Lilly cannot serve demand and need their formulary access.

Retatrutide's Phase 3 data shows that the higher discontinuation rate in lower-BMI patients observed in earlier cohorts extends to the broader trial population, creating a labeling restriction to higher-BMI obesity that limits the commercial opportunity. The triple agonist becomes a narrow-indication drug rather than the mass-market blockbuster the pipeline narrative implies.

Kisunla's commercial ramp remains slow as the diagnostic and infrastructure investment required to treat Alzheimer's patients proves harder to build than expected. Competitor Leqembi, backed by Biogen's established neurology commercial team, defends its first-mover advantage effectively.

In this scenario, Lilly misses 2026 revenue guidance, the stock derates from its growth-company valuation, and the multiple tirzepatide succession options in the pipeline become more speculative than near-term. The business remains fundamentally strong - the underlying franchise is real and the products work - but near-term financial performance disappoints relative to elevated expectations.

Sources consulted:

• Eli Lilly Q4 2025 Earnings Call Transcript - The Motley Fool
• Eli Lilly Q3 2025 Earnings Call Transcript - The Motley Fool
• Eli Lilly Q2 2025 Earnings Call Transcript - The Motley Fool
• Eli Lilly Q1 2025 Earnings Call - Investing.com
• Eli Lilly Q4 2024 Financial Results - PR Newswire
• Eli Lilly Company Wikipedia
• GLP-1 Receptor Agonist Market Size - Grand View Research
• Lilly vs Novo Nordisk - 247 Wall St
• CDK4/6 Inhibitors 2025 Revenue - Solt DB
• Lilly Manufacturing Expansion - CNBC
• Lilly $9 Billion Indiana Investment - PR Newswire
• Kisunla EU Approval - Investor.lilly.com
• Orforglipron Phase 3 - Lilly Investor Relations
• Retatrutide Phase 3 - BioSpace